Songli Pharmaceuticals: Selected oral insulin receptor agonist peptide ASC36 for clinical development.

Gelei Pharmaceutical announced on the Hong Kong Stock Exchange that the company has selected its first oral pancreatic oligopeptide ASC36 oral tablet as the target for clinical development. It is expected to submit a new drug clinical trial application for ASC36 oral tablets for the treatment of obesity to the US Food and Drug Administration in the second quarter of 2026.